Annual Report 2018 - GSK

www.gsk.com

Improving GSK’s pipeline of new medicines remains the first priority for investment. We also continue to invest behind key products, including increasing the manufacturing capacity of . Shingrix, GSK’s very successful new vaccine to help prevent shingles. Dividend payments form part of the Group’s capital allocation

  Annual, Report, Annual report, Improving, Improving gsk